Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 4,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Branch II Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura

NCT01485367
View directory record Official record
Conditions
Senile Purpura
Interventions
adapalene gel 0.3%
Drug
Lead sponsor
Multispecialty Aesthetic Clinical Research Organization
Other
Eligibility
52 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Woodland Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

NCT02360644
View directory record Official record
Conditions
Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
Aurora, Colorado • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

NCT00296036
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
231
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 23, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional Results available

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

NCT04015336
View directory record Official record
Conditions
Papillomavirus Infections, Oropharyngeal Neoplasms
Interventions
E7 T-Cell Receptor (TCR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

NCT00721214
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
5-azacytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 23, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex 25 mg, Placebo, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Not applicable Interventional

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

NCT01008930
View directory record Official record
Conditions
Solid Tumors, Cancer
Interventions
HR PEM Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 23, 2026, 2:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NCT02971501
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Not applicable Interventional

The Alabama NSAIDs Patient Safety Survey, Phase II: Reducing Disparities in Risk Awareness and Communication

NCT01352832
View directory record Official record
Conditions
Pain Management
Interventions
Interactive DVD, Usual Care
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

NCT00645411
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
Biological
Lead sponsor
Novartis
Industry
Eligibility
3 Years to 17 Years
Enrollment
3,604 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
16
States / cities
Fayetteville, Arkansas • Downey, California • Bardstown, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 23, 2026, 2:03 PM EDT
Recruiting Phase 2 Interventional

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
138
States / cities
Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

NCT03916419
View directory record Official record
Conditions
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
Interventions
ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel, Carboplatin AUC, Durvalumab
Device · Radiation · Drug + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

NCT02009865
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Epanova, Olive Oil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Not applicable Interventional

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

NCT04471844
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Optune®
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
86
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

NCT07407582
View directory record Official record
Conditions
Solid Tumor Malignancies, Testicular Cancer, Head and Neck Cancer, Thoracic Cancer
Interventions
Pedmark® STS
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

NCT00471887
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
CP-675,206
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 23, 2026, 2:03 PM EDT
Active, not recruiting Not applicable Interventional

Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer

NCT04266886
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Metastatic Cervical Cancer
Interventions
Best Practice, Hypnotherapy, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531
View directory record Official record
Conditions
Plasma Cell Neoplasm
Interventions
Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

NCT01723202
View directory record Official record
Conditions
Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Bhavana Konda
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00064350
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
141
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 23, 2026, 2:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

NCT02055820
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Venetoclax, Cyclophosphamide, Obinutuzumab, Rituximab, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 23, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional Results available

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

NCT03787303
View directory record Official record
Conditions
Metastatic Breast Cancer, Thyroid Dysfunction
Interventions
Triiodothyronine (T3)
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 105 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 23, 2026, 2:03 PM EDT
Active, not recruiting Phase 2 Interventional

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

NCT05709574
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Tadalafil 20 MG
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 2:03 PM EDT